Biblio
Stem cell mobilization yields with daratumumab and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther. 2022.
Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022.
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma. Cancer. 2024.
Peripheral Immunotype Correlates with Minimal Residual Disease Status and is Modulated by Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. Biol Blood Marrow Transplant. 2018.